Related coverage linked through entity extraction aliases.
Aug 01, 2026
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Jun 22, 2026
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
May 07, 2026
Madrigal expands MASH pipeline with siRNA licensing deals from Arrowhead and Ribo. Ribo deal includes $60M upfront and up to $4.4B milestones; IND submissions planned for 2026.
Jul 12, 2026
Savara resubmits BLA with near-term FDA decision expected; Sarepta reports $331M in Q1 net product revenue but Elevidys sales continue to decline; AstraZeneca stock falls ahead of July 2026 earnings release.
Apr 04, 2026
Arrowhead Pharmaceuticals is in focus after first-quarter results moved from a year-ago loss to profitability and the company shifted from the S&P 600 to the S&P 400. Investors are also watching progress in its RNAi pipeline, including two Phase 3 therapies, while valuation measures show a mixed picture.
Mar 29, 2026
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
